← Back to all trials
Completed
NCT06858995
Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)
Conditions: Administration of Therapy
Sex: Male
Ages: 18 Years – 99 Years
Healthy volunteers: No
Enrollment: 107
Sponsor: Central Hospital, Nancy, France
Location: CHRU de NANCY Vandœuvre-lès-Nancy
Summary
According to Pluvicto® indication, most of patients treated are elderly, with limited/poor venous peripheric access but they received previously chemotherapy through TIVAP and TIVAP generally stays in the body of patients when they are referred for Pluvicto® therapy. This is why TIVAP could be an interesting alternative for administering of 177Lu-PSMA-617. The aim of this study is to assess potential retention of 177Lu-PSMA-617 on TIVAP during administration through in vitro/ex vivo experimentations then in in vivo analysis.
Eligibility Criteria
Inclusion Criteria:
* Patients with an injection of Pluvicto as part of the treatment of their prostate cancer, having had a SPECT/CT scan for dosimetry within 2 to 4 hours after injection.
Exclusion Criteria:
* Patients who have refused to have their data used for research purposes
Source: ClinicalTrials.gov (NCT06858995). StuddyBuddy aggregates publicly available trial information.
